FDA Approves Ryzneuta® for Chemotherapy-Induced Neutropenia
Evive Biotech (Evive), and Acrotech Biopharma (Acrotech), a subsidiary of Aurobindo Pharma USA Inc., have announced that the U.S. Food and Drug Administration has approved Ryzneuta®. Ryzneuta (Efbemalenograstim alfa), is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Neutropenia is a common side effect of chemotherapy and is characterized by persistently low levels of neutrophils (a type of white blood cell with infection-fighting functions) due to the use of chemotherapy and other types of anti-cancer drugs, which increases the risk of adverse reactions such as infection and fever in cancer patients during chemotherapy.
Ryzneuta is a novel long-acting Granulocyte colony-stimulating factor (G-CSF), which can stimulate the proliferation, differentiation, and release of neutrophil precursors. It helps to enhance the immune function of cancer patients and to prevent the side effects of neutropenia caused by chemotherapy.
